title: The effect of the Rho-associated protein kinase inhibitor, HA-1077, in the rabbit ocular hypertension model induced by water loading.
abstract: OBJECTIVE
  The aim of this study was to investigate the intraocular pressure (IOP)-lowering effect of a new anti-glaucoma drug, the Rho-associated protein kinase (ROCK) inhibitor, HA-1077, in a rabbit ocular hypertension model.
  
  
  METHODS
  Experiments were carried out in 18 male New Zealand white rabbits, with ocular hypertension induced by water loading. Animals were divided into three groups followed by topical administration of 1 mM, 2 mM, and 3 mM HA-1077 in the left eye. As a control, phosphate buffered saline was administered in the opposite eye.
  
  
  RESULTS
  After administration of HA-1077 eye drops, there was a significant time- and dose-dependent decrease of the IOP. While minor conjunctival injection was seen in a few cases, no abnormalities of the anterior chamber or fundus were observed.
  
  
  CONCLUSIONS
  This is the first report of the effect of the ROCK inhibitor, HA-1077, on the IOP in an ocular hypertension model. Study results indicated that HA-1077 has a strong IOP-lowering effect.
authors.affiliation: Department of Ophthalmology, Graduate School of Medicine, Mie University, Tsu, Mie, Japan.
authors.forename: Takaki
authors.initials: T
authors.lastname: Fukunaga
authors.forename: Kengo
authors.initials: K
authors.lastname: Ikesugi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nishio
authors.forename: Masahiko
authors.initials: M
authors.lastname: Sugimoto
authors.forename: Mikio
authors.initials: M
authors.lastname: Sasoh
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Hidaka
authors.forename: Yukitaka
authors.initials: Y
authors.lastname: Uji
mesh_terms: D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D000287:Administration, Topical; D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D011817:Rabbits; D013312:Stress, Physiological; D013997:Time Factors; D014867:Water; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors*
chemical_list: D009883:Ophthalmic Solutions; D047428:Protein Kinase Inhibitors; D014867:Water; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D054460:rho-Associated Kinases; C049347:fasudil